Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
BioScience Health Innovations, Inc (BHIC) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of BioScience Health Innovations, Inc $0.86, price $7.11, upside -87.9%, quality 60 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
BH
Thin data
Sep 27, 2026
Thin data
Sep 27, 2026
BioScience Health Innovations, Inc
BHIC · USStructural break: The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Stretched ValuationStrong overvaluation with only moderate quality.
!Fair value $0.8600 · Strongly overvalued (−87.9%)
✓Quality 60/100
!Expensive Growth (revenue 3y +334.5 %/yr)
!Loss over the last twelve months · -14.7% net margin (TTM) · fiscal year 2025 11.3%
✓generates free cash flow
!Trails peers (1/10)
!Narrow moat 17/100
!Evidence only low, so the estimate is less certain
Watch BioScience Health Innovations, Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range $1.75 – $52.00 · fair‑value band $0.4400 – $1.16 · the $7.11 price screens above the $0.8600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow BioScience Health Innovations in your weekly email
Every Wednesday you see whether BioScience Health Innovations is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
BioScience Health Innovations, Inc. operates as a health and wellness innovation company focuses on mitochondrial health science, advanced peptide delivery, and metabolic care in the United States.
Show more
BioScience Health Innovations, Inc. operates as a health and wellness innovation company focuses on mitochondrial health science, advanced peptide delivery, and metabolic care in the United States. It offers nutritional supplements, peptides, and bioactive compounds through its core technology Mineral Oxide Delivery System, as well as provides Oracle NetSuite, an accounting and financial reporting system. The company also provides services, including testosterone and hormonal Optimization, NAD+ and cellular health, and platform licensing and peptide delivery. It sells its products through Amazon platform; and direct-to-consumer. The company was formerly known as Nowtransit Inc and changed its name to BioScience Health Innovations, Inc. in February 2025. BioScience Health Innovations, Inc. is based in Bluffdale, Utah.
Stock analysis
BioScience Health Innovations, Inc (BHIC) currently trades at $7.11, while our model-based Fair Value estimate is $0.8600, implying the stock looks roughly 726.4% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $2.54 per share, and 0 of the 20 models we run sit above the $7.11 price.
Bear case: the Growth DCF group reads lowest at $0.2300, and 20 of the 20 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.4400 (bear) to $1.16 (bull), the price of $7.11 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
BioScience Health Innovations, Inc reported revenue of $5.7M in FY2025 versus $69.3K in FY2022, a compound +334.5%/yr. Reported net income was $642K in FY2025.
Key figures
Market cap $81.2M · P/E ratio 139.3 · P/S ratio 15.7 · EPS (TTM) $−0.0600 · Net margin 11.3% · Return on equity −37.0% · Return on assets (EBIT) −189% · Operating margin −21.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 23% below its 52-week high and 306% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −88%, BHIC screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely ($0.0800 to $2.59). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear $0.4400
Fair Value $0.8600
Bull $1.16
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$0.1700
$0.2200
$0.3600
72
Growth DCF
$0.1700
$0.2300
$0.3400
71
EPV
$0.4000
$0.4400
$0.4800
68
All 20 models by family
DCF Models
FCF DCF
$0.1700
$0.2200
$0.3600
72
5Y Revenue Exit
$0.4800
$0.8800
$1.73
61
5Y P/E Exit
$0.6800
$1.61
$2.89
60
10Y Revenue Exit
$0.3500
$0.8600
$1.24
58
10Y P/E Exit
$0.4900
$1.23
$2.49
53
Earnings-Based
Graham-Dodd
$0.3700
$2.59
$3.64
59
Lynch FV
$1.34
$1.91
$2.49
57
PEG = 1.0
$1.34
$1.91
$2.49
53
EPV
$0.4000
$0.4400
$0.4800
68
Multiples
P/E Multiple
$0.9000
$1.20
$1.50
63
P/S Multiple
$0.7000
$0.9300
$1.16
58
P/B Multiple
$0.4200
$0.5700
$0.7100
55
EV/EBIT
$0.8400
$1.10
$1.36
63
EV/Revenue
$0.6100
$0.8500
$1.09
51
Asset-Based
NCAV (Graham)
$0.0600
$0.0800
$0.1300
50
Growth DCF
Growth DCF
$0.1700
$0.2300
$0.3400
71
Rev-Margin DCF
$0.5300
$1.00
$1.97
61
Economic Profit
Residual Income
$0.2700
$0.4400
$1.05
58
ROIC Compounder
$0.4600
$0.5800
$0.7100
66
Growth Earnings
Growth-Adj P/E
$1.78
$2.54
$3.30
63
Notify me when BHIC reaches fair value
Put BHIC on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
60/100
Of which business quality 66 · Market factors (momentum, volatility) 66
Profitability
90
Margins and returns on capital today
Quality Growth
75
Are margins and returns improving?
Cashflow
25
Earnings quality: real cash, not paper profit
Fin. Strength
100
Balance sheet, leverage, solvency risk
Investment
50
Disciplined investing over empire-building
Low Volatility
27
Calm price path (market factor)
Momentum
80
Price trend over the last 3–12 months (market factor)
52W Momentum
86
Distance to the 52-week high (market factor)
Net Issuance
42
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+208.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+334.5%
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−245.8% (2022) → 12.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
A lot of optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
more than +80 %
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
BHIC screens 726% overvalued. Compare with Alibaba Health Information Technology Limited →
Compare BioScience Health Innovations, Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 59 stocks
Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Alibaba Health Information Technology Limited 0241 | HK$2.83 | HK$2.34 | −17% |
| Yifeng Pharmacy Chain Co 603939 | ¥22.08 | ¥40.59 | +84% |
| DaShenLin Pharmaceutical Group 603233 | ¥17.55 | ¥26.45 | +51% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥12.95 | ¥14.25 | +10% |
| MedPlus Health Services Limited MEDPLUS | ₹654.90 | ₹393.38 | −40% |
| Yixintang Pharmaceutical Group 002727 | ¥10.60 | ¥9.51 | −10% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥14.85 | ¥16.34 | +10% |
| ShuYu Civilian Pharmacy Corp 301017 | ¥13.25 | ¥5.91 | −55% |
| Apotea AB APOTEA | kr 83.70 | kr 46.46 | −44% |
| Luyan Pharma Co 002788 | ¥10.89 | ¥15.91 | +46% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is BioScience Health Innovations, Inc (BHIC) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.8600 versus a price of $7.11, about −88% upside (overvalued).
What is the fair value of BHIC?
Our model-based fair value for BioScience Health Innovations, Inc is $0.8600 (as of Sep 27, 2026), built from audited fundamentals. The current price: $7.11.
What is the quality score of BHIC?
BioScience Health Innovations, Inc has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BioScience Health Innovations, Inc (BHIC)?
Our model-based price target is the fair value of $0.8600 (as of Sep 27, 2026) from 20 valuation models. Cautious scenario $0.4400, optimistic scenario $1.16. It is a calculation from audited fundamentals, not an analyst target.
What is the BioScience Health Innovations, Inc stock forecast for 2026?
Our models put fair value at $0.8600, about −88% upside versus a price of $7.11 (overvalued). Cautious scenario $0.4400, optimistic scenario $1.16. The calculation is refreshed regularly with new filings.
What is the revenue of BioScience Health Innovations, Inc (BHIC)?
BioScience Health Innovations, Inc reported trailing-twelve-month revenue of about $4.5M (latest available figure, as of Sep 27, 2026).
What growth is priced into BioScience Health Innovations, Inc (BHIC)?
For today's price to be fair in a discounted-cash-flow model, BioScience Health Innovations, Inc would have to grow free cash flow by more than 80 % per year for five years (discount rate 13.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +334.5 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of BHIC use?
Our models discount BioScience Health Innovations, Inc at 13.0 %: a base by market capitalisation (micro), damped by beta 1.09, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For BioScience Health Innovations, Inc that is more than 80 % per year a year over ten years, using the same discount rate (13.0 %) and the same formula as our fair value.
How much growth has BioScience Health Innovations, Inc (BHIC) delivered so far?
Over the past 3 years revenue at BioScience Health Innovations, Inc grew +334.5 % a year. The price currently implies more than 80 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of BioScience Health Innovations, Inc (BHIC) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into BioScience Health Innovations, Inc (more than 80 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of BioScience Health Innovations, Inc (BHIC)?
The free-cash-flow yield on the price is 0.14 %: that much free cash flow BioScience Health Innovations, Inc produces per unit of market value. When it exceeds the discount rate of our models (13.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of BioScience Health Innovations, Inc (BHIC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BioScience Health Innovations, Inc it is $0.8600 per share (as of Sep 27, 2026), against a price of $7.11. It is the blended result of 20 valuation models (cash flow, earnings, asset, dividend).
Is BioScience Health Innovations, Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, BHIC trades above its calculated fair value: price $7.11, fair value $0.8600, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BHIC?
No. The price is what the market pays today ($7.11); the fair value is what the company's own numbers justify ($0.8600). For BioScience Health Innovations, Inc the two are $6.25 per share apart. That gap is exactly why we show both numbers side by side.
How much is BioScience Health Innovations, Inc worth?
The market values BioScience Health Innovations, Inc at about $81.2M (market capitalisation, as of Sep 27, 2026). Per share that is $7.11; our models calculate a fair value of $0.8600 per share.
What do the bullish and bearish scenarios say about BHIC?
Our models span a range for BioScience Health Innovations, Inc: cautious scenario $0.4400, base $0.8600, optimistic $1.16 per share (as of Sep 27, 2026, price $7.11). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BHIC?
BioScience Health Innovations, Inc trades at a price-to-earnings ratio of 139.3 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.8600 is built from several models across several years. Other multiples: P/S 18.1.
How solid is the balance sheet of BioScience Health Innovations, Inc (BHIC)?
Balance-sheet figures for BioScience Health Innovations, Inc (as of Sep 27, 2026): return on equity −37.0%. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is BHIC from its 52-week high?
BioScience Health Innovations, Inc trades at $7.11, about 23% below its 52-week high of $9.20 and 306% above the low of $1.75 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.8600 is for.
Which stocks are comparable to BioScience Health Innovations, Inc?
From the same area (Healthcare) we also value Alibaba Health Information Technology Limited, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BioScience Health Innovations, Inc stock attractive at the current price?
The data as of Sep 27, 2026: price $7.11, calculated fair value $0.8600 (−88%), Quality Score 60/100, from 20 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BHIC calculated?
We run BioScience Health Innovations, Inc through 20 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.8600, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. BioScience Health Innovations, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BioScience Health Innovations, Inc (BHIC)?
The closing price on Sep 25, 2026 was $7.11. Our model-based fair value is $0.8600, about −88% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BioScience Health Innovations, Inc right now?
The price sits above even our optimistic bull case ($1.16). The favourable scenario is already priced in. The model range is unusually wide ($0.4400 to $1.16). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of BioScience Health Innovations, Inc
How large is the market capitalisation of BioScience Health Innovations, Inc (BHIC)?
The market capitalisation of BioScience Health Innovations, Inc is $81.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BioScience Health Innovations, Inc (BHIC)?
The price-to-sales ratio of BioScience Health Innovations, Inc is 15.7 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BioScience Health Innovations, Inc (BHIC)?
Earnings per share at BioScience Health Innovations, Inc are $−0.0600 (price ÷ EPS = P/E 139.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of BioScience Health Innovations, Inc (BHIC)?
The net margin of BioScience Health Innovations, Inc is 11.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BioScience Health Innovations, Inc (BHIC)?
The return on equity (ROE) of BioScience Health Innovations, Inc is −37.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BioScience Health Innovations, Inc (BHIC)?
On an EBIT basis the return on assets of BioScience Health Innovations, Inc is −189% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BioScience Health Innovations, Inc (BHIC)?
The operating margin of BioScience Health Innovations, Inc is −21.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BioScience Health Innovations, Inc (BHIC)?
Revenue at BioScience Health Innovations, Inc is growing −41.0% versus a year earlier (3y avg +335%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
Free · no account needed
Watch BioScience Health Innovations, Inc in the live analysis
One click puts BioScience Health Innovations, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.